SELLAS Shares Surge Following Positive Phase 3 Leukemia Vaccine Trial Results
SELLAS Life Sciences stock tripled, reaching a new 52-week high after reporting that its experimental cancer vaccine reduced the risk of death in acute myeloid leukemia patients by 41%.
🧠AI AnalysisPhoto: Benzinga
Key points
- SELLAS shares jumped 183.13% to a 52-week high of $21.14 on Tuesday.
- The Phase 3 REGAL trial met its primary endpoint, cutting the risk of death by 41%.
- Median overall survival reached 24.0 months for vaccine recipients versus 14.7 months for control treatments.
- The company targets a Biologics License Application submission in the first half of 2027.
Stock Skyrockets on Trial Data
Shares of SELLAS Life Sciences Group Inc. surged 183.13% to trade at $21.14 on Tuesday, touching a fresh 52-week peak. Trading activity spiked dramatically, with session volume reaching 57.567 million shares compared to a typical daily average of roughly 6.897 million.
The drastic equity move followed the release of topline data from the pivotal randomized Phase 3 REGAL clinical study. The trial assessed galinpepimut-S, an immunotherapy vaccine intended for acute myeloid leukemia patients who had achieved remission following previous salvage therapy but could not undergo a stem cell transplant.
Survival Metrics and Safety
According to the company, the late-stage evaluation successfully hit its main endpoint by demonstrating a statistically significant boost in overall survival. Treatment with the vaccine lowered the risk of mortality by 41%, registering a hazard ratio of 0.59 and a two-sided p-value of 0.035.
Patients administered the immunotherapy achieved a median overall survival duration of 24.0 months, outperforming the control cohort receiving the best available treatment, who recorded 14.7 months. The vaccine maintained a favorable safety profile aligned with historical clinical findings, displaying no unexpected adverse events.
Regulatory Plans
Following the successful trial outcome, the biopharmaceutical firm intends to consult with federal regulators regarding an expedited approval pathway. Management aims to submit a Biologics License Application during the first half of 2027.
What to watch next: Upcoming discussions between SELLAS management and federal health regulators regarding the planned 2027 Biologics License Application submission.
Source Benzinga — benzinga.com/trading-ideas/movers/26/11/63344384/sellas-stock-tripl… ↗
Read next
🧠AI AnalysisBitcoin Technical Outlook Signals Persistent Bearish Structure Despite Short-Term Bounce
Bitcoin remains constrained by a broader bearish pattern on short-term charts as dynamic trendline resistance caps recovery attempts. Although price recently rebounded fr…
🧠AI AnalysisMapping Out a $500 Stake in Two Emerging Quantum Computing Enterprises
A breakdown of a $500 allocation into Infleqtion and Xanadu reveals the high-risk, high-reward nature of early-stage quantum computing investments.
🧠AI AnalysisBitcoin Eyes Resistance Near $61,800 Following Support Bounce
Bitcoin displays bullish momentum after rebounding from a key support zone, with potential movement toward the 61,800 resistance level.
🧠AI AnalysisAnalyst Suggests Taking Profits on Global X MSCI Colombia ETF
Market analysts recommend locking in gains on Colombian equities amid current macroeconomic conditions.
🧠AI AnalysisAnthropic IPO Momentum Fades as Stock Slips Below Opening Levels
Anthropic shares declined following a strong market debut, prompting market watchers to evaluate potential short-term downside risks.
📈MarketsBitcoin Tests Critical Monthly Support Level as Traders Watch for Breakdown or Rebound
Bitcoin is hovering near a vital monthly support level, with technical analysts warning that a close below this threshold could risk a drop toward the $32,000 region.